Focus: Ascendis Pharma is a public-stage biopharmaceutical company specializing in prodrug therapies (TransCon platform) across oncology, endocrinology, ophthalmology, neurology, and rare diseases. The company is headquartered in Palo Alto, CA with a focused pipeline of late-stage clinical programs.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Cooling — net -11 jobs in 30d
14 added, 25 removed. Slower than typical.
Ascendis offers exposure to late-stage rare disease wins and a novel platform, but the recent layoff and modest hiring pipeline suggest internal restructuring may limit career growth in the near term.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Only approved product and sole near-term revenue driver; CNP agonist with 8+ years of patent protection and first-in-class potential in achondroplasia.
Help build intelligence for Ascendis Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ascendis Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent WARN filing is a material red flag—signals execution concerns and possible further restructuring; job stability is moderate-to-high risk.
Recent peer-reviewed publications with author affiliations at this company
+1 more
+1 more
+2 more
+1 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo